Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

‘Development of hypoxia-activated quadruplex DNA binders as potential cancer therapeutics’

Project description

Smart drugs against cancer

Many chemotherapy regimens such as cisplatin target DNA, causing non-specific side effects in normal cells. Therefore, there is a pressing need for new, more specific and effective anti-cancer drugs. The EU-funded G4Redox project addresses this problem by developing compounds that leave double-stranded DNA intact and target transient G-quadruplex DNA structures that form during replication and transcription. Moreover, these drugs become activated only in the presence of low oxygen levels such as in the case of the tumour microenvironment. Researchers envision combining these drugs with other anti-cancer pharmaceuticals for a synergistic effect.

Objective

Cancer is the second leading cause of death globally. In spite of the great advances in cancer therapy over the past two decades, there is still a pressing need to develop new therapies with reduced side effects caused by conventional therapies. Historically, many chemotherapeutic approaches to treat cancer, have targeted DNA. But targeting genomic DNA has some disadvantages such as undesired side effects due to low selectivity of most chemotherapeutics (e.g. cisplatin and alkylating agents).
In this project I aim to address this problem via the development of ‘smart’ compounds that have the following features: (i) target G-quadruplex DNA structures instead of duplex DNA; this non-canonical DNA topologies form transiently during replication and transcription (as well as in the telomeric region) and have been identified as attractive targets for anticancer drugs (ii) developing compounds that are only activated in tumors and not in healthy tissue to achieve this, I have designed pro-drugs that are only activated in the hypoxic (low levels of oxygen) conditions present in tumors and only when activated can target G-quadruplex DNA (iii) my ‘smart’ compounds will not only target G-quadruplex DNA once activated but will release a second drug able to target other cancer molecular targets (e.g. topoisomerase I, COX-2) to cause a cumulative response of the chemotherapeutic agent. I expect to see significant synergism between the different chemotherapeutics released upon activation of the pro-drug. This synergy in the activities is expected to play an important role to overcome drug resistance. The multidisciplinary nature of the project is strong. The proposal includes both way transfer of knowledge between the host group at Imperial College of London and the candidate in new advanced skill sets and techniques. The proposed work will expand my experience, research competencies, and professional networks, enhancing the development of my career as an independent researcher.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-MSCA-IF-2020

See all projects funded under this call

Coordinator

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 224 933,76
Address
SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
SW7 2AZ London
United Kingdom

See on map

Region
London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 224 933,76
My booklet 0 0